PILL Direxion Daily Pharmaceutical & Medical Bull 3X ETF

ETF 13.93 Delayed

ETF quote, holdings, sector allocation, technicals, and options analytics. Expected move IV rank history Fibonacci levels

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

PILL $13.93 —
Key stats
$13.93
52-Week Range
$8.79 – $24.15
YTD
+18.45%
IV Rank (30D)
82.74
Straddle Price
$2.45
P/C Vol Ratio
1.16
Open
$14.70
Day Range
$13.77 – $14.70
Volume
38,237
Prev Close
$14.55
About

Direxion Daily Pharmaceutical & Medical Bull 3X ETF (PILL) ETF

No description available.

Exchange
ARCX
Inception
2017-11-15
Has Options
Yes
Fund profile
holdings as of Nov 18, 2026issuer datathrough Jul 2026flows, SEC filings
Resets to 3x its benchmark's return each day. Over longer periods the result compounds and can differ sharply from 3x the benchmark, especially when it is volatile. Decay analysis
Expense ratio
0.98%
prospectus, filed Mar 3, 2026
Assets
$16M
shares × price, Nov 18, 2026
Trailing yield
0.41%
paid quarterly
Average daily volume
$978K
30 sessions
Holdings
67
top 10 are 253.2%
Listed
Nov 15, 2017
NYSE Arca
Last fee change
+1 bp
filed Feb 26, 2026
Closure risk, 12 months
1.2%
low: volatility · model
Tracking difference
-8.96 pts
vs index, after fees, FY 2025
FrenzyCap ETF score
33
how it is built
Cost48
Liquidity33
Scale8
Diversificationn/a

Moves with. Small caps over large (23% of its variance, beta 2.92); US large-cap stocks (14% of its variance, beta 1.61). These factors explain 42% of its daily moves over the last year.

Stated objective. The Fund seeks daily investment results, before fees and expenses, of 300% of the daily performance of the Index. The Fund does not seek to achieve its stated investment objective for a period of time different than a trading day. (from the fund's prospectus)

All 67 holdingsFlow historySimilar fundsOverlap toolAll Leveraged Equity ETFs

Fund flows
through Jul 2026SEC filings
Jul 2026
+$8K
latest reported month
Latest 3 months
+$914K
+4.4% of assets
Latest 12 months
−$3.9M
−18.8% of assets
Aug 2025: +$377KSep 2025: −$796KSepOct 2025: −$792KNov 2025: +$1.0MNovDec 2025: +$14KJan 2026: +$1.2M+$1.2MJanFeb 2026: −$1.3MMar 2026: −$4.0M−$4.0MMarApr 2026: −$557KMay 2026: +$676KMayJun 2026: +$230KJul 2026: +$8KJul
View as a table
Net flows of PILL by month, Aug 2025 to Jul 2026
MonthNet flow
Jul 2026+$8K
Jun 2026+$230K
May 2026+$676K
Apr 2026−$557K
Mar 2026−$4.0M
Feb 2026−$1.3M
Jan 2026+$1.2M
Dec 2025+$14K
Nov 2025+$1.0M
Oct 2025−$792K
Sep 2025−$796K
Aug 2025+$377K

Net creations and redemptions from the fund's SEC filings, which become public about 60 days after each quarter. Every month since 84 months ago

Similar funds
FundOverlapFeeAssets1Y
XPHState Street SPDR S&P Pharmaceuticals ETF57%0.35%$508M+25.0%compare
IHEiShares U.S. Pharmaceuticals ETF30%0.37%$1.7B+32.0%compare
PJPInvesco Pharmaceuticals ETF22%0.58%$594M+24.5%compare
FTXHFirst Trust Nasdaq Pharmaceuticals ETF14%0.60%$1.1B+36.5%compare
PPHVanEck Pharmaceutical ETF13%0.36%$1.1B+18.9%compare

Ranked by how much of the two portfolios is the same securities.

Look-through: what the holdings say
weights as of Nov 18, 2026issuer data
Holdings vs fair value
+18.4%
50% under, 15% over · 100% covered
Price / earnings
—
52% loss-making · 98% covered
Price / book · sales
3.0 · 2.6
revenue growth +8.4%
Above 200-day average
61%
53% above 50-day · by weight
Short interest
11.4%
of float, weighted · 7.3 days to cover
Insider buying
6%
of weight had net insider buying, 90 days; 45% net selling
13F holders
+5.5%
change in shares held by institutions, latest quarter
Reporting earnings
0.0%
of weight in 7 days; 0.0% in 14
Largest contributors below fair value
Largest contributors above fair value

Each figure is the fund's holdings weighted by position size, using our data on those stocks, and covers only the share of the stock holdings stated. Positive fair value means the holdings trade below our estimate.

What changed in the portfolio
Nov 16, 2026 → Nov 17, 2026
ActionHoldingWeight beforeWeight afterShares vs flows
ExitPCRXPACIRA BIOSCIENCES INC1.36%——

0 new, 0 exited, 0 increased and 0 decreased between the fund's two latest holdings reports; turnover 10.4%. Full holdings and history

Under the hood
fiscal year to Oct 31, 2025SEC census
Authorized participants
4 active
of 4 with agreements; top 3 did 95%
Created · redeemed
$6.5M · $9.3M
over the fiscal year
Redemptions in kind
100%
creations 100% in kind
Creation unit
50,000
shares
Securities lending
2.39%
of assets on loan on average; earned 2.6 bp
Return vs index
-8.96 pts
after fees; -8.02 before
Diversification status
Non-diversified
may concentrate in fewer issuers

From the fund's annual census filing with the SEC. In-kind redemptions are what let an ETF shed appreciated securities without realising gains.

ETF Profile
holdings as of 2026-11-18
Holdings
67
AUM
$55.8M
Provider
Direxion
Inception
2017-11-15
Exchange
ARCX
Data As Of
2026-11-18
Expense Ratio
0.98%
Dividend Yield
0.41%
Distribution
Quarterly
Recent distributions
Ex-Date Pay Date Amount Type
2026-09-22 2026-09-29 $0.0009 CD
2026-06-23 2026-06-30 $0.0152 CD
2026-03-24 2026-03-31 $0.0109 CD
2025-12-23 2025-12-31 $0.0326 CD
2025-09-23 2025-09-30 $0.0098 CD
2025-06-24 2025-07-01 $0.0245 CD
Asset Allocation
Top Holdings
top 50 of 67 holdings
Symbol Name Weight % Asset Class Country
— SPSIPH SWAP ASSET LEG 108.07% Derivative —
— SPSIPH SWAP ASSET LEG 71.85% Derivative —
— SPSIPH SWAP ASSET LEG 54.03% Derivative —
— GOLDMAN FINL SQ TRSRY INST 506 21.14% Cash/Money Market —
— DREYFUS GOVT CASH MAN INS 16.43% Cash/Money Market —
— GOLDMAN SACHS FIN GOV 465 INSTITUT 11.12% Cash/Money Market —
— SPSIPH SWAP ASSET LEG 9.18% Derivative —
XERS XERIS BIOPHARMA HOLDINGS INC 2.63% Equity (US) US
MANE VERADERMICS INC 1.52% Equity (US) US
LLY ELI LILLY & CO 1.52% Equity (US) US
VTRS VIATRIS INC 1.50% Equity (US) US
AMRX AMNEAL PHARMACEUTICALS INC 1.48% Equity (US) US
MAZE MAZE THERAPEUTICS INC 1.44% Equity (US) US
ZTS ZOETIS INC 1.37% Equity (US) US
RPRX ROYALTY PHARMA PLC- CL A 1.37% Equity (Foreign) GB
PRGO PERRIGO CO PLC 1.33% Equity (US) US
ELAN ELANCO ANIMAL HEALTH INC 1.32% Equity (US) US
ETON ETON PHARMACEUTICALS INC 1.31% Equity (US) US
COLL COLLEGIUM PHARMACEUTICAL INC 1.29% Equity (US) US
JNJ JOHNSON & JOHNSON 1.26% Equity (US) US
PFE PFIZER INC 1.24% Equity (US) US
LGND LIGAND PHARMACEUTICALS 1.23% Equity (US) US
OGN ORGANON & CO 1.23% Equity (US) US
JAZZ JAZZ PHARMACEUTICALS PLC 1.20% Equity (Foreign) IE
PBH PRESTIGE CONSUMER HEALTHCARE 1.19% Equity (US) US
ANIP ANI PHARMACEUTICALS INC 1.19% Equity (US) US
SEPN SEPTERNA INC 1.19% Equity (US) US
MRK MERCK & CO. INC. 1.17% Equity (US) US
EWTX EDGEWISE THERAPEUTICS INC 1.17% Equity (US) US
BMY BRISTOL-MYERS SQUIBB CO 1.15% Equity (US) US
TARS TARSUS PHARMACEUTICALS INC 1.14% Equity (US) US
AMPH AMPHASTAR PHARMACEUTICALS IN 1.06% Equity (US) US
INVA INNOVIVA INC 1.05% Equity (US) US
AMLX AMYLYX PHARMACEUTICALS INC 1.03% Equity (US) US
MBX MBX BIOSCIENCES INC 1.02% Equity (US) US
SUPN SUPERNUS INC 1.01% Equity (US) US
LQDA LIQUIDIA CORP 0.99% Equity (US) US
ELVN ENLIVEN THERAPEUTICS INC 0.98% Equity (US) US
TRVI TREVI THERAPEUTICS INC 0.98% Equity (US) US
HRMY HARMONY BIOSCIENCES HOLDINGS 0.96% Equity (US) US
HROW HARROW INC 0.95% Equity (US) US
DFTX DEFINIUM THERAPEUTICS INC 0.93% Equity (US) —
LBRX LB PHARMACEUTICALS INC 0.88% Equity (US) US
OMER OMEROS CORP 0.87% Equity (US) US
ZVRA ZEVRA THERAPEUTICS INC 0.80% Equity (US) US
AXSM AXSOME THERAPEUTICS INC 0.78% Equity (US) US
CORT CORCEPT THERAPEUTICS INC 0.73% Equity (US) US
ANRO ALTO NEUROSCIENCE INC 0.73% Equity (US) US
NUVB NUVATION BIO INC 0.72% Equity (US) US
PAHC PHIBRO ANIMAL HEALTH CORP-A 0.69% Equity (US) US
Non-Equity Breakdown
Direxion Daily Pharmaceutical & Medical Bull 3X Shares · NPORT-P period 2026-07-31 (filed 2026-09-28)
Net assets: $21M · 73 total positions · equity 75.02% · non-equity 54.61%
Non-equity holdings — 7 positions, 54.61% of NAV
Category Weight Value Positions
Short-term investment 32.53% $6.7M 3
DO 22.08% $4.6M 4
Chart

Markers: Click a marker type to show or hide it. Earnings turn amber when the stock moved more than options implied; hollow markers are still to come, or insider trades under a 10b5-1 plan. Intraday times are New York time; shaded bars are pre-market and after-hours.

Seasonality
Month'21'22'23'24'25'26Avg
Jan1.14%-19.06%21.10%0.64%15.56%-1.19%3.03%
Feb1.10%-6.37%-18.33%10.45%-2.05%2.00%-2.20%
Mar-20.04%14.29%-12.65%-9.97%-0.14%-20.03%-8.09%
Apr-6.99%-28.59%4.01%-20.10%-11.51%15.70%-7.91%
May6.23%0.64%-20.17%-0.46%-0.57%-3.04%-2.90%
Jun8.23%2.66%9.49%-6.33%-4.26%51.76%10.26%
Jul-13.39%0.09%17.65%24.40%1.52%9.08%6.56%
Aug-14.55%-5.83%1.69%8.76%44.46%9.70%7.37%
Sep-7.28%-14.94%-26.99%2.76%0.62%-21.84%-11.28%
Oct-0.71%11.24%-25.11%8.99%6.59%1.67%0.45%
Nov-17.88%-0.29%6.37%-1.88%30.54%-1.64%*2.54%
Dec4.61%-15.11%34.78%-20.40%11.92%--3.16%
Total-48.83%-51.76%-26.34%-11.77%118.81%28.34%1.41%
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $15.31
SMA 50: $15.65
SMA 200: $15.11
Current: $14.03
EMA 12: $15.31
EMA 26: $15.45
MACD: -0.1379 | Signal: -0.1150
BEARISH
ADX (14): 16.26
RANGE
+DI: 19.36
−DI: 30.41

Momentum Oscillators

RSI (14): 42.26
NEUTRAL
Stoch %K: 14.87
Stoch %D: 26.39
Williams %R: -93.14

Volume & Volatility

BB Upper: $17.62
BB Lower: $13.00
NEUTRAL
OBV: 2,155,073
Vol SMA 20: 73,291
Vol ROC: -67.39%
ATR: $1.12
True Range: $0.93
HV 20: 97.6%
HV 30: 93.0%
HV 60: 79.4%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-11-20T00:00:00 – 2026-11-18T00:00:00
AI Analysis

LLM Stock Analysis Report: PILL

Executive Summary:

Overall Assessment: BEARISH with confidence level 6/10

Key Drivers:

  • Technical indicators suggest a potential reversal, as the stock price approaches the upper Bollinger Band.
  • High volatility, reflected in the beta and average true range (ATR), may lead to increased market uncertainty.

Primary Risks:

  • Earnings miss or negative news could exacerbate downward pressure on the stock.
  • Options activity suggests a low IV rank, which may indicate historically high volatility.

Investment Thesis: PILL's recent price action is likely driven by a combination of technical and fundamental factors. The stock appears to be trading near its upper Bollinger Band, indicating potential resistance. As the stock approaches this level, I expect increased volatility and potentially even a reversal.

Recent News Sentiment Impact: None available

Technical Analysis:

Trend Direction: Medium-term downtrend (1-3 months)

Support/Resistance Levels:

  • Upper Bollinger Band: $8.84
  • Lower Bollinger Band: $7.39
  • SMA 200: $6.61
  • EMA 12: $8.19

Momentum Signals:

  • RSI (14): 54.66 (neutral)
  • MACD: 0.18 / Signal: 0.00 / Histogram: 0.18 (bullish)
  • Bollinger Bands: neutral signal

Volume Analysis: Volume trends suggest a mixed signal, with increased volume on the recent price increase.

News & Sentiment Analysis:

Recent Headlines Summary: No recent news available

Sentiment Assessment: Neutral sentiment due to lack of recent news

Catalyst Identification: None identified

Market Narrative: The market is likely waiting for earnings or other fundamental data to drive future stock performance.

Risk & Volatility Assessment:

Beta Interpretation: High risk relative to the market (beta >1.2)

Volatility Regime: Current volatility levels are high compared to historical averages

Options Market Signals:

  • IV Rank: 6.0% (Low)
  • Put/Call Volume Ratio: 0.17 (Bullish sentiment)
  • Options market pricing a $0.97 move by expiration

Market Context & Positioning:

Sector Performance: Neutral sector performance

Institutional Activity: Mixed institutional activity, with both buyers and sellers present

Correlation Analysis: Correlated with the market (R-squared 0.65)

Relative Valuation: Trading near its upper Bollinger Band, indicating potential resistance.

Key Levels & Action Items:

  • Critical Price Levels: $8.84 (upper Bollinger Band) and $7.39 (lower Bollinger Band)
  • Breakout/Breakdown Levels: None identified
  • Time-Sensitive Catalysts: Earnings or other fundamental data expected to drive future stock performance
  • Risk Management: Consider setting stop-loss levels at the lower Bollinger Band ($7.39) or just above the SMA 200 ($6.61).

Please note that this analysis is based on the provided data, and actual market conditions may vary.

Generated

PILL Options Activity & IV Rank

PILL IV rank history, 52-week IV rank and IV percentile →

Volatility Metrics

Current IV: 78.8%
7-DTE IV: —
Expected Move: $2.45
7-DTE Move: $0.77
Days to Exp: 29 (2026-12-18)

Options Flow · All expiries

Call Volume: 107
Put Volume: 124
P/C Volume: 1.159
NEUTRAL
Call OI: 204
Put OI: 125
P/C OI: 0.613
Total OI: 329

ATM Options Pricing

ATM Call: $1.35
ATM Put: $1.10
Call %: 9.7%
Put %: 7.9%

Chain Summary

Chain Volume: 231
Chain OI: 329
Last Updated: 11/19/2026

PILL Implied Volatility

30-day IV
78.8%
Nov 19
IV rank
83High
Within its 90-session range

Loading implied volatility…

The 30-day IV is the at-the-money implied volatility of options 30 days out, the blue line. The band is its 20-session average, 2 standard deviations either side. Realized volatility is how much PILL actually moved over the last 20 sessions, from closing prices, on the same yearly scale. Without earnings takes each earnings report out of the 30-day IV, sized from what options paid for past reports, so it shows whether options are expensive or cheap apart from the report. Click a name above the chart to show or hide it.

Spread Scanner

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Scanning bull put, bear call, iron condor and calendar spreads…

Dealer Positioning
TYPICAL γ

Estimated net dealer gamma is at the 44th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.

Gamma percentile
44%
vs own history
GEX tilt
+0.22
OI-weighted, today
Vanna tilt
+1.00
δ-sensitivity to IV
Charm tilt
-1.00
δ-decay vs time
Vanna tilt +1.00: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -1.00: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.

Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.

Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.

Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.

This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.

· 4 ATM contracts, 0k total OI
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Put vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Call vs ATM
IV(call wing) − IV(ATM), in vol points

The same measure on the upside: how the OTM call is priced against the at-the-money strike.

  • Negative (typical) — calls trade below ATM for most stocks and indices, so the sign alone says little.
  • Percentile vs own history: high = upside calls unusually rich for this name (squeezes, takeover talk, commodity supply scares); low = calls cheaper than usual.
Reading them together

Put or call vs ATM tells you how expensive that tail is. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d put —
— pts EXTREME
No data
30 DTE / 10d put —
— pts EXTREME
ATM 78.3% / Put —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Loading the implied volatility surface…

Volatility Smile

Loading the implied volatility smile…

IV Rank (7 DTE)
IV Rank (30 DTE)82.7HighNov 19

Embed PILL IV rank

PILL's 30-day IV rank (90 sessions) with its 52-week rank, at-the-money IV and a 90-session trend. Updates after each close. Paste the code into any web page or blog post. Email newsletters drop iframes, so link to the page there.

Theme
Preview
Straddle Price (30 DTE)$2.45Nov 19
Beta Analysis

Risk Metrics

Beta: 2.4431
Alpha: 37.11%
Correlation: 0.4697
R-Squared: 22.1%
Stock Volatility: 71.7%
Market Volatility: 13.8%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
Beta & Alpha Over Time

PILL Institutional Ownership (13F)

Filings for 2026-06-30 · 2 already for 2026-09-30

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

5 filers117,192 shares$2.09M value
# Filer Shares Value % of Total % of Float Period
1 Susquehanna International Group, LLP Custodian 74,692 $1.35M 64.48% — 2026-06-30
2 GTS SECURITIES LLC 25,390 $458.54K 21.92% — 2026-06-30
3 Jane Street Group, LLC Custodian 11,187 $177.76K 8.50% — 2026-09-30
4 Tower Research Capital LLC (TRC) Custodian 5,823 $105.16K 5.03% — 2026-06-30
5 FINANCIAL CONSULATE, INC 100 $1.59K 0.08% — 2026-09-30
# Filer Notional Value % of Total Period
# Filer Notional Value % of Total Period
Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
75.41K
SI % of Float
6.86%
Days to Cover
1.23
Short Vol Ratio
38.1%
Free Float
—
Float %
—
Short interest 2026-10-30 • Short volume 2026-11-18
PILL Constituent Performance

Click any bar to view the full quote for that stock.

PILL Constituents (59 of 59)
Symbol Name Weight % Price 1 Day 1 Week 1 Month
XERS XERIS BIOPHARMA HOLDINGS INC 2.63% $16.55 -2.59%-0.60%+52.39%
MANE VERADERMICS INC 1.52% $123.89 -0.78%-8.43%-10.54%
LLY ELI LILLY & CO 1.52% $1356.61 -1.89%-4.95%+3.82%
VTRS VIATRIS INC 1.50% $19.96 -1.58%-3.43%+8.01%
AMRX AMNEAL PHARMACEUTICALS INC 1.48% $21.41 -2.13%-1.31%+4.57%
MAZE MAZE THERAPEUTICS INC 1.44% $32.16 +3.09%-10.88%+0.67%
ZTS ZOETIS INC 1.37% $82.5 -3.58%-0.55%+0.62%
RPRX ROYALTY PHARMA PLC- CL A 1.37% $68.11 -0.81%-1.24%+6.85%
PRGO PERRIGO CO PLC 1.33% $16.37 -3.36%+1.17%+0.00%
ELAN ELANCO ANIMAL HEALTH INC 1.32% $26.72 +0.07%+0.83%+17.76%
ETON ETON PHARMACEUTICALS INC 1.31% $62.31 +0.52%+1.41%+24.58%
COLL COLLEGIUM PHARMACEUTICAL INC 1.29% $25.35 -2.24%+1.60%+7.87%
JNJ JOHNSON & JOHNSON 1.26% $267.31 -1.97%-5.72%-0.11%
PFE PFIZER INC 1.24% $27.71 -1.25%-3.88%-8.91%
LGND LIGAND PHARMACEUTICALS 1.23% $291.15 -2.53%-7.94%-5.42%
OGN ORGANON & CO 1.23% $13.92 +0.00%+0.14%+1.24%
JAZZ JAZZ PHARMACEUTICALS PLC 1.20% $238.68 -3.67%-0.71%+11.19%
PBH PRESTIGE CONSUMER HEALTHCARE 1.19% $50.3 -0.63%+10.99%+1.70%
ANIP ANI PHARMACEUTICALS INC 1.19% $69.82 -2.31%-1.75%-5.33%
SEPN SEPTERNA INC 1.19% $39.96 +1.29%-4.54%-2.25%
MRK MERCK & CO. INC. 1.17% $133.1 -3.40%-9.42%-9.60%
EWTX EDGEWISE THERAPEUTICS INC 1.17% $41.65 +0.66%-9.11%+4.14%
BMY BRISTOL-MYERS SQUIBB CO 1.15% $58.87 -1.16%-5.54%-6.56%
TARS TARSUS PHARMACEUTICALS INC 1.14% $77.33 +1.82%+0.57%+7.28%
AMPH AMPHASTAR PHARMACEUTICALS IN 1.06% $28.3 -4.73%-1.96%+8.70%
INVA INNOVIVA INC 1.05% $18.37 -0.16%-3.16%-12.77%
AMLX AMYLYX PHARMACEUTICALS INC 1.03% $26.55 -0.26%-11.09%-7.07%
MBX MBX BIOSCIENCES INC 1.02% $53.99 +1.07%-0.95%+7.00%
SUPN SUPERNUS INC 1.01% $28.66 -1.05%-1.87%-30.47%
LQDA LIQUIDIA CORP 0.99% $57.16 +1.35%-1.65%+44.02%
ELVN ENLIVEN THERAPEUTICS INC 0.98% $46.69 +4.01%-3.35%+11.35%
TRVI TREVI THERAPEUTICS INC 0.98% $14.16 +4.81%+3.96%+9.43%
HRMY HARMONY BIOSCIENCES HOLDINGS 0.96% $32.91 -0.62%-2.65%-8.67%
HROW HARROW INC 0.95% $32.33 +0.53%+14.24%+14.85%
DFTX DEFINIUM THERAPEUTICS INC 0.93% $29.62 +1.72%-10.24%-17.72%
LBRX LB PHARMACEUTICALS INC 0.88% $40.34 +0.70%-4.99%+2.33%
OMER OMEROS CORP 0.87% $13.94 -4.19%-22.51%-17.32%
ZVRA ZEVRA THERAPEUTICS INC 0.80% $9.07 -2.26%-18.73%-12.20%
AXSM AXSOME THERAPEUTICS INC 0.78% $135.34 +1.00%-6.25%-13.28%
CORT CORCEPT THERAPEUTICS INC 0.73% $64.91 -4.25%-11.94%-39.62%
ANRO ALTO NEUROSCIENCE INC 0.73% $25.96 +0.19%-15.22%+16.94%
NUVB NUVATION BIO INC 0.72% $3.83 +1.46%-5.54%-18.40%
PAHC PHIBRO ANIMAL HEALTH CORP-A 0.69% $34.34 -3.46%-3.16%-13.74%
WVE WAVE LIFE SCIENCES INC 0.64% $2.75 -0.90%-13.00%-18.06%
OCUL OCULAR THERAPEUTIX INC 0.63% $5.89 -0.76%-6.13%-10.82%
RAPP RAPPORT THERAPEUTICS INC 0.61% $23.68 +1.20%-8.39%-10.74%
ALMS ALUMIS INC 0.60% $4.37 -0.68%-28.79%-36.00%
AQST AQUESTIVE THERAPEUTICS INC 0.56% $3.74 -1.06%+4.76%-9.44%
PHAT PHATHOM PHARMACEUTICALS INC 0.52% $5.14 -3.02%-17.50%-26.68%
AVLN AVALYN PHARMA INC 0.51% $27.7 +0.04%-9.45%+1.65%